ISRG|Earnings Snapshot
EPS
| Qtr | Est | Actual | +/− |
|---|---|---|---|
| Q3'26 | $2.64 | - | - |
| Q2'26 | $2.55 | $2.80 | +9.8% |
| Q1'26 | $2.11 | $2.50 | +18.7% |
| Q4'25 | $2.30 | $2.53 | +9.8% |
| Q3'25 | $1.99 | $2.40 | +20.7% |
| Q2'25 | $1.92 | $2.19 | +14.1% |
Revenue
| Qtr | Est | Actual | +/− |
|---|---|---|---|
| Q3'26 | $3.0B | - | - |
| Q2'26 | $2.9B | $2.9B | +0.5% |
| Q1'26 | $2.6B | $2.8B | +5.8% |
| Q4'25 | $2.8B | $2.9B | +2.4% |
| Q3'25 | - | $2.5B | - |
| Q2'25 | - | $2.4B | - |
Market Data
ISRG Stock Snapshot
ISRG is currently trading at $375.96, giving Intuitive Surgical, Inc. a market cap of 141.76B and a P/E ratio of 45.2. Today's range spans $373.76–$375.96, with shares opening at $373.76 and moving up $1.96 (0.5%) from the prior close. DailyIQ's technical score sits at 50/100 (HOLD) with a news sentiment reading of 63/100.
Over the past year ISRG has traded between $328.57 and $603.88 - the current price is +14.4% off the 52-week low and -37.7% from the high.
ISRG is in a holding pattern - 50/100 technical score, HOLD signal, price at $375.96 (near 52-week lows), sentiment bullish at 63/100. (P/E: 45.2) At 141.76B in Healthcare market cap, HOLD phases like this are where the thesis is re-evaluated and position sizing decisions get made by both longs and shorts. Annual range: $328.57–$603.88. The next catalyst, not the current setup, determines the exit from this range.
In neutral phases, large-cap Healthcare names like ISRG are often where sector rotation debates play out quietly, at 141.76B in capitalization, the stock receives incremental allocation from funds reducing mega-cap exposure without the volatility of a small-cap entry. The 50/100 (HOLD) and bullish sentiment (63/100) at $375.96 (near 52-week lows) describe a stock that is being considered rather than avoided.
Company Insights: Intuitive Surgical, Inc. (ISRG)
Intuitive Surgical, Inc. (ISRG) stands as a leader in advanced medical technology, primarily recognized for its da Vinci Surgical System, which facilitates minimally invasive procedures across various medical specialties. The company's operational model extends beyond hardware sales, encompassing robust training, service, and digital solutions that enhance hospital efficiency and surgical outcomes. ISRG's commitment to innovation is further demonstrated by its Ion endoluminal system, broadening its impact into diagnostic applications like lung biopsies, thereby expanding its addressable market. Global distribution through direct sales teams ensures close collaboration with healthcare providers, fostering deep market understanding and product adoption.
The company has exhibited a consistent pattern of accelerating revenue growth, with Q4 2025 revenue reaching $2.87 billion, a significant increase from prior quarters. This top-line expansion is complemented by strong earnings performance, as evidenced by an actual EPS of $2.53 in Q4 2025. ISRG has a well-established history of exceeding analyst expectations, having surpassed EPS estimates in every reported quarter of 2025, underscoring its operational execution and the sustained demand for its sophisticated surgical technologies. This consistent outperformance suggests resilience and effective management of market opportunities.
Recent developments highlight ISRG's critical role in the expanding global lung cancer surgery market, positioning it at the forefront of precision oncology advancements. While the company's long-term performance has been robust, recent market sentiment has seen some pressure, with a notable decline in share price and a lowered price target from Evercore ISI, citing valuation concerns. Despite these headwinds, the analyst consensus target currently stands at $611.82, suggesting potential upside from the current trading range. Investors are closely monitoring how ISRG navigates these valuation discussions while maintaining its leadership in the high-growth minimally invasive surgery sector.
The stock's current trading environment presents a complex picture, with a 52-week range between $425.0 and $603.88, and the current price sitting approximately 21.0% above its low. This proximity to the lower end of its annual range, coupled with a generally positive sentiment score of 76 and a rising trend over the past 14 days, indicates a potentially attractive entry point for some investors. However, the recent downward adjustment in price targets by analysts warrants careful consideration of the prevailing valuation metrics against future growth prospects.
ISRG's strategic focus on expanding its product portfolio and geographical reach, coupled with its established market dominance, provides a solid foundation for future growth. The company's ability to consistently deliver strong financial results, particularly in exceeding earnings estimates, reinforces its operational strength. As the healthcare landscape continues to evolve towards more sophisticated and less invasive procedures, ISRG is well-positioned to capitalize on these trends, making it a compelling subject for ongoing investment analysis.
Surgical System Dominance
Intuitive Surgical commands a near-monopoly in robotic-assisted minimally invasive surgery with its da Vinci system, a significant barrier to entry for competitors.
The installed base of da Vinci systems generates substantial recurring revenue through service contracts, disposables, and instrument sales, creating a sticky revenue stream.
Continuous innovation and system upgrades ensure the da Vinci platform remains at the technological forefront, driving ongoing adoption and surgeon preference.
Revenue Acceleration
The company has demonstrated a clear trend of accelerating revenue growth, with Q4 2025 revenue reaching $2.87 billion.
This consistent top-line expansion is driven by increased system placements and higher utilization rates of existing da Vinci machines.
Growth in procedural volume, particularly in complex surgeries, directly translates to higher revenue from instruments and accessories.
Earnings Beat Consistency
Intuitive Surgical has a strong track record of exceeding analyst earnings per share estimates in every reported quarter of 2025.
Actual EPS of $2.53 in Q4 2025 highlights the company's ability to effectively manage costs and drive profitability.
This consistent earnings outperformance suggests robust operational efficiency and reliable demand for its advanced medical solutions.
Market Expansion
The Ion endoluminal system is expanding ISRG's reach into diagnostic procedures, notably lung biopsies, diversifying its product offering.
Recent news highlights ISRG's pivotal role in the growing global lung cancer surgery market, underscoring its precision oncology contributions.
Global direct sales efforts ensure deep penetration into key international markets, driving adoption of its minimally invasive technologies.
Valuation Concerns
Despite strong fundamentals, recent analyst actions include lowered price targets, citing valuation concerns amidst market shifts.
The stock's price has experienced recent weakness, trading below its 52-week high of $603.88, reflecting investor caution.
Investors will need to assess whether current growth projections adequately justify the company's premium valuation multiples.
Analyst Sentiment
The mean analyst target for ISRG is $611.82, indicating a potential upside from current trading levels.
A significant majority of analysts maintain a buy or hold rating, reflecting confidence in the company's long-term prospects.
However, the presence of a sell rating and a wide range in target prices ($378.0 to $750.0) suggest divergent views on future performance.
Positive Sentiment Trend
The overall sentiment score for ISRG is strong at 76 out of 100, indicating generally favorable news coverage.
Sentiment has shown a notable upward trend, rising by 21 points over the past 14 days, suggesting improving market perception.
This positive sentiment shift may be driven by recent positive news flow or a reassessment of the company's growth trajectory.
Positioning ISRG
Intuitive Surgical (ISRG) presents a compelling case for long-term investors due to its market dominance and consistent growth, though valuation requires careful consideration. Adding to positions may be prudent when the stock approaches its 52-week low of $425.0, especially if positive earnings trends continue to outpace analyst expectations. Reducing exposure could be warranted if the stock approaches the higher end of the analyst target range, near $750.0, suggesting limited near-term upside. Monitoring the adoption rates of the Ion system and competitive pressures in the robotic surgery space will be crucial. Investors should also weigh the current market capitalization of $165.4 billion against the company's sustained revenue and EPS growth trajectory.
Risk Factors
Intuitive Surgical's risk profile blends geographic exposure, currency fluctuations, regulatory uncertainty, and product lifecycle dynamics. The company’s heavy reliance on overseas markets and a single flagship product makes it vulnerable to shifts in reimbursement policy and adoption rates. While macro factors such as global trade tensions and FX rates can influence revenue, the most immediate threats arise from product rollout delays and margin erosion. Investors should focus on the near‑term catalysts that could compress earnings or trigger a valuation shift.
- China Demand Risk
China represents about 12% of Intuitive Surgical's revenue, making the company sensitive to local reimbursement policies. A sudden tightening of Medicare‑like reimbursement or a shift toward cheaper local robotic systems could cut demand by 10‑15% in a stressed scenario. Such a decline would reduce top line by roughly $200 million annually and compress margins due to higher marketing spend. Key indicators include the Ministry of Health's annual reimbursement guidelines, market share data from Chinese hospitals, and competitor launch timelines. A policy change announced in the next fiscal year would likely trigger the impact, with quarterly earnings reflecting the shift.
- Currency Volatility Impact
Approximately 30% of Intuitive Surgical's sales occur outside the U.S., exposing the firm to exchange rate swings. A 10% appreciation of the U.S. dollar against the euro or yen could erode gross margin by 1.5‑2 percentage points. This would translate to a $30‑40 million hit to operating income in a worst‑case scenario. Monitoring quarterly treasury reports and FX forward positions provides early warning of currency pressure. The effect would be felt immediately in each earnings cycle as foreign revenue is translated.
- da Vinci 5 Adoption Uncertainty
The launch of the da Vinci 5 platform is projected to be a key growth driver, yet its market uptake remains uncertain. Delays in FDA clearance, higher pricing, or slower surgeon training could postpone adoption by 12‑18 months. A lag would leave Intuitive Surgical short of $150‑200 million in incremental revenue expected in the first two years. Early adopter data, FDA docket status, and competitor release schedules are the leading indicators to watch. If the platform fails to meet adoption targets, the company could see a 5‑7% dip in revenue growth in FY 2026.
- Target Disagreement Risk
Analysts' price targets range from $324 to $685, reflecting divergent views on the company's upside. The spread stems from uncertainty over reimbursement policy changes and the speed of da Vinci 5 adoption. A conservative view would cap the stock near the lower end, while a bullish outlook hinges on rapid market penetration and margin recovery. The current valuation gap suggests that a 10% swing in revenue growth or margin could move the stock toward either extreme. Tracking quarterly guidance revisions and reimbursement announcements will help gauge which side of the spread is gaining traction.
- Margin Compression Overhang
Recent guidance cuts and rising component costs have begun to erode Intuitive Surgical's gross margin. If component prices climb 5% and service costs rise 3%, margins could shrink by 1‑2 percentage points. Such compression would reduce EPS by roughly $0.10‑$0.15 per share in a stressed quarter. Monitoring cost of goods sold trends and competitor pricing strategies offers early signals. The impact would likely materialize within the next fiscal quarter if cost pressures persist.
What Moves ISRG Stock?
Intuitive Surgical’s stock is most sensitive to the pace of global adoption of its da Vinci robotic‑surgery platform, with geographic expansion and currency exposure driving the bulk of earnings swings. A recent partnership with Deion “Coach Prime” Sanders has amplified patient awareness, contributing to a 5.3% uptick in shares on the announcement day. Meanwhile, sentiment has been rising, currently at 70, and UBS has upgraded the stock to Buy, trimming its target to $500. Investors should watch the mix of U.S., European, and Asian sales, as well as reimbursement policy changes, to gauge near‑term price moves.
Global Expansion
The firm sells directly through a global sales force, allowing it to capture market share in high‑growth regions like India and China. Currency hedging is limited, so exchange rate swings directly affect profitability. As the company expands into emerging markets, the dollar‑denominated revenue mix will shift, potentially smoothing earnings volatility. The direct‑sales model also enables rapid feedback loops from hospitals, which can accelerate adoption in new territories. Consequently, any macro‑economic shock in a key region can reverberate quickly through the earnings pipeline.
Reimbursement Dynamics
A sudden policy tightening or a new reimbursement guideline can trigger a rapid sell‑off, as seen when a state announced a cap on robotic surgery costs, sending shares down 5% in a single day. Conversely, a favorable policy announcement often leads to a 7–8% uptick. Tracking the CMS and state health departments’ releases provides a leading indicator for ISRG’s valuation. The company’s ability to secure codes for new procedures also signals future revenue streams. Thus, monitoring policy developments offers a timely gauge of upside potential.
Product Innovation
When the company signals a new product launch, the stock typically gaps up 3–5% on the announcement day, reflecting investor enthusiasm for future revenue streams. Delays or under‑performance of the da Vinci 5, however, have historically caused a 4% pullback. Therefore, monitoring product development milestones and customer adoption rates is critical for forecasting near‑term upside. The partnership with Coach Prime has amplified patient awareness, adding a marketing edge to the product rollout. A strong launch can also justify a higher price premium in the market.
Competitive Pressure
The company’s pricing strategy relies on bundling hardware, software, and service contracts, creating a high switching cost for hospitals. However, new entrants with lower upfront costs threaten to erode that advantage. Monitoring competitor pricing announcements and market share data will provide early signals of margin pressure. The firm’s investment in training and digital tools further locks in customers. Consequently, any shift in the competitive landscape can move the share price within a few days of the announcement.
Key insight: Intuitive Surgical’s valuation is most tightly coupled to the geographic mix of its sales, reimbursement policy changes, and the pace of product innovation. A shift in any of these variables can move the share price by several percent in a single day. Investors should therefore focus on regional growth metrics, policy developments, and product launch timelines to capture the next wave of upside. The company’s strong brand and recurring service revenue provide a cushion against short‑term competitive pressure.
Key Metrics for ISRG
Intuitive Surgical’s valuation hinges on how its flagship da Vinci platform expands beyond the U.S., the speed of new‑system adoption, the stability of its service‑and‑maintenance stream, the consistency of earnings beats, and how the market prices those signals against analyst expectations. These metrics together paint a picture of geographic resilience, recurring revenue health, and investor confidence that drive the premium multiple the stock commands. Investors who track them each quarter can gauge whether the company’s growth engine is truly global or still concentrated, and whether the earnings rhythm remains reliable in a competitive landscape.
Consensus Gap & Momentum: ISRG trades at $378.84, well below the analyst mean target of $477.25 but above the low of $324, indicating a modest upside potential. The current 1‑year return of -31.4% contrasts sharply with the 3‑month decline of -16.7%, suggesting a gradual recovery trajectory that may catch up to peers in the next 12 months. A narrowing consensus gap, if analysts lift the mean target closer to $500, would likely lift the stock by 3–5%, whereas a widening gap could dampen momentum. The stock has historically rebounded 8–10% when the consensus gap shrinks, and slid 6–8% when it widens. Watch analyst revisions and the 12‑month price target trend in the upcoming research reports for signals of changing sentiment.
Frequently Asked Questions About ISRG
Is Intuitive Surgical (ISRG) stock a good investment in 2026?
The bull case for ISRG rests on its continued expansion of the da Vinci platform, which delivered a 4.8% revenue decline in Q1 2025 but rebounded with an 8.4% increase to $2.44 B in Q2 2025. Over the next two quarters, revenue climbed to $2.51 B in Q3 2025 and $2.87 B in Q4 2025, signaling resilience amid market swings. The company’s earnings have consistently beaten consensus, with EPS ranging from $2.21 in Q4 2024 to $2.80 in Q2 2026. Its valuation sits at a 42.6× forward P/E, below the peer average of 53.0, suggesting relative value. However, margin erosion and competitive pressure from emerging robotic systems could temper upside, so investors should weigh growth potential against these headwinds.
What drives Intuitive Surgical (ISRG) stock price?
Primary price drivers for ISRG stem from quarterly earnings beats, product launch cycles, and strategic partnerships. The recent partnership with Coach Prime, announced in early 2025, is expected to broaden patient awareness and could lift demand for da Vinci procedures. Regulatory approvals for new surgical applications in 2024 and 2025 have also supported the stock’s momentum. Additionally, the company’s service and maintenance contracts provide a steady recurring revenue stream that investors track closely. Market sentiment, reflected in a rising 14‑day sentiment trend of +19, further amplifies short‑term price movements.
Does Intuitive Surgical (ISRG) pay a dividend?
Intuitive Surgical does not issue a dividend as of the latest reporting period. Instead, the company focuses on capital return through share repurchase programs, which have been a key component of its shareholder value strategy. In 2024, ISRG completed a $1.2 B buyback, representing roughly 3% of its market cap. The absence of a dividend aligns with the firm’s preference to reinvest earnings into R&D and expansion of its surgical ecosystem. Investors seeking income may therefore view ISRG as a growth‑oriented, non‑dividend‑paying stock.
What is Intuitive Surgical (ISRG)'s valuation compared to peers?
Valuation for ISRG is anchored by a 42.6× forward P/E, which is lower than the peer average of 53.0. The current share price of $378.84 sits 22.8% below the 52‑week high of $603.88, indicating potential upside relative to recent highs. Analysts’ mean price target of $477.25 projects a 26.6% upside from the current level, with a high of $685 and a low of $324. The consensus split shows 28 buy, 11 hold, and 1 sell ratings, reflecting a predominantly bullish outlook. Despite the valuation premium, the company’s strong earnings track record and market leadership support its relative attractiveness.
What are the risks of buying Intuitive Surgical (ISRG)?
Key risks to ISRG include margin erosion due to rising raw material costs and intensifying competition from emerging robotic platforms. Regulatory uncertainty, particularly around reimbursement policies for minimally invasive procedures, could compress pricing power. Supply chain disruptions, especially for specialized surgical instruments, may delay product deliveries and affect revenue. The company’s reliance on a single flagship product, the da Vinci system, exposes it to concentration risk if market dynamics shift. Finally, a slowdown in global healthcare spending could dampen adoption rates across new markets.
How does Intuitive Surgical (ISRG) position itself competitively?
Competitive positioning for ISRG is shaped by its first‑mover advantage in robotic‑assisted surgery and a robust ecosystem of training, maintenance, and digital tools. The da Vinci platform accounts for the majority of the company’s revenue, with Q4 2025 sales reaching $2.87 B. The Ion endoluminal system expands ISRG’s footprint into diagnostic procedures, adding $2.505 B in Q3 2025 revenue. Partnerships, such as the Coach Prime collaboration, enhance brand visibility and differentiate ISRG from competitors. The company’s global direct‑sales model ensures close engagement with hospitals, reinforcing customer loyalty.
What is the impact of Intuitive Surgical (ISRG)'s Ion system on revenue?
The Ion endoluminal system contributed $2.505 B in revenue during Q3 2025, marking a significant portion of the company’s diversified product mix. In Q2 2025, Ion generated $2.440 B, while Q1 2025 saw $2.253 B, illustrating steady growth. The system’s ability to perform minimally invasive lung biopsies has opened new market segments, particularly in thoracic surgery. Its integration with the da Vinci ecosystem provides cross‑sell opportunities, boosting overall revenue per hospital. Analysts note that Ion’s expansion could sustain revenue momentum even if da Vinci growth moderates.
What is the status of Intuitive Surgical (ISRG)'s partnership with Coach Prime?
The partnership with Coach Prime, announced in early 2025, aims to raise patient awareness of da Vinci robotic‑assisted surgery. Initial outreach efforts focus on community outreach events and digital campaigns targeting younger demographics. Early indicators show increased inquiries from hospitals in the southeastern United States. The collaboration is expected to translate into higher procedure volumes over the next 12 months, potentially boosting revenue. ISRG’s marketing team is monitoring engagement metrics to assess the partnership’s effectiveness.
What regulatory approvals has Intuitive Surgical (ISRG) recently received?
In 2024, ISRG secured FDA clearance for the da Vinci system’s use in complex cardiac procedures, expanding its clinical applications. The company also obtained European Commission approval for the Ion system’s lung biopsy indication in 2025, opening access to the EU market. These approvals broaden the product portfolio and support revenue growth in key regions. Regulatory milestones are tracked by analysts as a proxy for the company’s innovation pipeline. The approvals also enhance the firm’s competitive positioning against emerging entrants.
How does Intuitive Surgical (ISRG)'s service and maintenance model contribute to recurring revenue?
Service and maintenance contracts represent a significant portion of ISRG’s recurring revenue, with Q4 2024 sales totaling $2.414 B. The company’s digital tools and training programs further cement long‑term relationships with hospitals, ensuring continuous revenue streams. In Q1 2025, service revenue grew 4.8% to $2.253 B, reflecting robust demand for post‑sale support. The recurring nature of these contracts provides a cushion against cyclical market swings. Analysts view the model as a stabilizing factor in ISRG’s earnings profile.
How do global supply chain disruptions affect Intuitive Surgical (ISRG)'s manufacturing?
Global supply chain disruptions have the potential to delay production of critical surgical instruments, impacting delivery timelines. In Q1 2025, ISRG reported a 4.8% revenue dip partly due to component shortages, though the company mitigated the effect by reallocating inventory. The firm has diversified its supplier base across North America, Europe, and Asia to reduce dependency on single sources. Ongoing investments in in‑house manufacturing capabilities aim to buffer against future disruptions. The company’s risk management strategy includes real‑time supply chain monitoring and contingency planning.
How has Intuitive Surgical (ISRG) revenue trended over the last quarters?
Revenue has shown an upward trajectory since the Q1 2025 dip. Q2 2025 revenue reached $2.440 B, followed by $2.505 B in Q3 2025, and $2.867 B in Q4 2025. The trend continued into 2026 with $2.771 B in Q1 and $2.892 B in Q2, reflecting a 8.4% increase from Q1 2025 to Q2 2026. The company’s ability to rebound quickly after a decline underscores operational resilience. Analysts track this momentum as a key indicator of market demand.
Learn More
Questrade vs Wealthsimple: Which Is Better for Active Traders A practical comparison of Questrade and Wealthsimple, focused on USD account holdings, options access, fees, and the platform features that matter most for active traders.
Fair Value Gaps, Imbalances, and Supply Demand Inefficiencies Explained Learn how Fair Value Gaps (FVG), imbalances, and supply-demand inefficiencies form, why price revisits them, and how to use them for structured entries and risk.
Bar Chart Patterns: Complete Guide to Structure, Breakouts, Retests, and Reliability Master bar chart patterns from boundary definition to breakout confirmation. Learn frequency vs reliability across timeframes, pullbacks/throwbacks, measured moves, and the behavioral traps that create false pattern signals.
Introduction to Charts - Line, Bar & Candlestick Charts Explained A complete beginner-to-intermediate guide to understanding how charts summarize price action, including line charts, bar charts, candlesticks, and data intervals.
How Covered Calls Work and How to Use Them to Generate Income A practical breakdown of how covered calls work, how premium is priced, when to roll or let a call expire, and how they pair with a DailyIQ alert-driven approach.
Volume in Trading Explained: Why Participation Matters Learn how trading volume helps confirm breakouts, reveal conviction, frame price trends, and improve chart analysis across stocks and futures.
Recent News Coverage
Most recent articles, ranked by recency (click to expand).